Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
33 hedge funds and large institutions have $23.9M invested in Genocea Biosciences, Inc. in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 8 closing their positions.
12,017% more call options, than puts
Call options by funds: $2.79M | Put options by funds: $23K
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
3% less funds holding
Funds holding: 34 → 33 (-1)
19% less capital invested
Capital invested by funds: $29.4M → $23.9M (-$5.48M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$130K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$52.7K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$50.5K |
| 4 |
Bank of New York Mellon
New York
|
+$40.9K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
+$35.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$255K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$198K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$123K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$81.2K |
| 5 |
Millennium Management
New York
|
-$63K |
GNCA Hedge Fund Activity: Q1 2020 in Review
33 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2020, worth a combined $23.9M — down 19% from $29.4M a quarter earlier.
Fund positioning in GNCA was balanced in Q1 2020: 8 funds opened new positions, 8 closed out, 5 added to existing stakes and 9 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $130K. The largest seller was Renaissance Technologies, cutting an estimated $255K.
- 33 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2020, down from 34 in Q4 2019.
- Funds reported $23.9M of Genocea Biosciences, Inc. stock for Q1 2020, down 19% quarter-over-quarter.
- 8 funds opened new Genocea Biosciences, Inc. positions in Q1 2020 and 8 closed out, a net change of 0 holders.
- The largest Genocea Biosciences, Inc. buyer in Q1 2020 was Susquehanna International Group, an estimated $130K added.
- The largest Genocea Biosciences, Inc. seller in Q1 2020 was Renaissance Technologies, an estimated $255K sold.
Based on aggregated 13F filings for Q1 2020.